Clinical Trial Update: Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cabazitaxel in men aged 75 years or older with metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Castrate-resistant Metastatic Prostate Cancer | Phase 2 | Status: WITHDRAWN